Treating sleep apnoea aids glaucoma control

Article

Severe obstructive sleep apnoea (OSA) is an important risk factor for developing glaucoma and must be treated in those who have it to improve control of the eye disease, according to new research.

Severe obstructive sleep apnoea (OSA) is an important risk factor for developing glaucoma and must be treated in those who have it to improve control of the eye disease, according to new research published in Eye.

Researchers in Qatar assessed for glaucoma in 39 adults who had been diagnosed with moderate or severe OSA. They classified the severity of OSA as mild, moderate, or severe using American Association of Sleep Medicine (AASM) criteria and the apnoea hypopnoea index. All study participants underwent serial visual field tests, optical coherence tomography with fundus photography, and pachymetry before the study began, and they were followed in an ophthalmology outpatient clinic and a sleep clinic for 3 years.

The investigators discovered that 8 (20.5%) of the study participants who had OSA also had glaucoma; 6 (75%) of them had normal-tension glaucoma (NTG), and 2 (25%) had the high-tension version. Among the 27 participants in whom OSA was classified as severe, the eye disease was present in 7 (25.9%), and among 12 patients with moderate OSA, the eye disease was present in 1 (8.3%).

During follow-up, two participants in whom glaucoma originally had not been diagnosed were reclassified as having NTG. Also, the condition of two participants who had glaucoma deteriorated. A higher prevalence of glaucoma existed in those with severe OSA than in those with moderate OSA, although the difference was not statistically significant.

For more detailed information visit the journal's website.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.